Suchergebnisse - "Raugi, Dana N"

PubPharm (18)

1

Intrinsic resistance of HIV-2 and SIV to the maturation inhibitor GSK2838232

enthalten in: PloS one | 2023

von Smith, R. | Raugi, D. | Nixon, R. | +4

2

Spectrum of Activity of Raltegravir and Dolutegravir Against Novel Treatment-Associated Mutations in HIV-2 Integrase : A Phenotypic Analysis Using an Expanded Panel of Site-Directed Mutants

enthalten in: The Journal of infectious diseases | 2022

von Smith, R. | Wu, V. | Song, J. | +4

3

Trends in Reported Sexual Behavior and Y-Chromosomal DNA Detection Among Female Sex Workers in the Senegal Preexposure Prophylaxis Demonstration Project

enthalten in: Sexually transmitted diseases | 2020

von Roberts, D. | Hawes, S. | Bousso Bao, M. | +12

4

The Landscape of Persistent Viral Genomes in ART-Treated SIV, SHIV, and HIV-2 Infections

enthalten in: Cell host & microbe | 2019

von Bender, A. | Simonetti, F. | Kumar, M. | +21

CommentIn: Trends Microbiol. 2019 Oct;27(10):809-810. - PMID 31431318

5

Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants

enthalten in: Antimicrobial agents and chemotherapy | 2019

von Smith, R. | Raugi, D. | Wu, V. | +37

6

SD-chip enabled quantitative detection of HIV RNA using digital nucleic acid sequence-based amplification (dNASBA)

enthalten in: Lab on a chip | 2018

von Wang, J. | Kreutz, J. | Thompson, A. | +10

7

A Trial of a Single-tablet Regimen of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate for the Initial Treatment of Human Immunodeficiency Virus Type 2 Infection in a Resource-limited Setting : 48-Week Results From Senegal, West Africa

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2018

von Ba, S. | Raugi, D. | Smith, R. | +32

8

In Vitro Antiviral Activity of Cabotegravir against HIV-2

enthalten in: Antimicrobial agents and chemotherapy | 2018

von Smith, R. | Wu, V. | Zavala, C. | +36

9

The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1

enthalten in: Antimicrobial agents and chemotherapy | 2015

von Smith, R. | Raugi, D. | Wu, V. | +8

10

In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2

enthalten in: Retrovirology | 2015

von Smith, R. | Raugi, D. | Pan, C. | +5